Clinical Parkinsonism Related Disorders最新文献

{"title":"Correlation analyses between MIBG myocardial scintigraphy and monoamine levels in dementia with Lewy bodies show potential link with the serotonergic system","authors":"Annelies Heylen ,&nbsp;Yannick Vermeiren ,&nbsp;Sebastiaan Engelborghs ,&nbsp;Frank Van Acker ,&nbsp;Peter Paul De Deyn ,&nbsp;Debby Van Dam","doi":"10.1016/j.prdoa.2025.100346","DOIUrl":"10.1016/j.prdoa.2025.100346","url":null,"abstract":"<div><h3>Setting</h3><div>Dementia with Lewy bodies (DLB) remains poorly understood and frequently misdiagnosed, complicated by co-pathology with other dementia forms. DLB patients often present with autonomic dysfunction and peripheral Lewy body pathology alongside central lesions. Monoaminergic neurotransmitter systems seem an early target for DLB pathology, especially the noradrenergic system. Noradrenaline analogue ¹²³I-metaiodobenzylguanidine (MIBG) is considered an indicative biomarker for peripheral noradrenergic sympathetic denervation.</div></div><div><h3>Objectives</h3><div>Our aim was to measure paired monoaminergic levels and MIBG scintigraphy values in DLB patients, exploring a possible link between noradrenergic neurotransmission and peripheral denervation.</div></div><div><h3>Design</h3><div>44 patients with a possible DLB diagnosis entered the study. Peripheral uptake of ¹²³I-MIBG was determined by the heart-to-mediastinum (H/M) ratio, as a measure for noradrenergic sympathetic denervation. In cerebrospinal fluid (CSF), serum and plasma samples, monoamines ((nor)adrenaline ((N)A), 5-hydroxytryptamin (5-HT, serotonin), dopamine (DA)) and respective metabolites (3-methoxy-4-hydroxyphenylglycol (MHPG), 5-hydroxyindoleacetic acid (5-HIAA), homovanillic acid (HVA) and 3,4-dihydroxyphenylacetic acid (DOPAC)), were measured by means of reversed-phase ultrahigh-performance liquid chromatography with electrochemical detection.</div></div><div><h3>Results</h3><div>We found significant correlations between the H/M ratio and serum 5-HIAA, plasma 5-HT, plasma 5-HIAA/5-HT and plasma HVA/5-HIAA, but no further correlations with the noradrenergic system. CSF-serum MHPG, CSF-serum DOPAC, CSF-serum HVA, CSF-plasma MHPG, CSF plasma NA, CSF-plasma DOPAC, CSF-plasma MHPG/NA and CSF-plasma DOPAC/DA were significantly correlated.</div></div><div><h3>Conclusions</h3><div>These results show an association between the H/M ratio and serotonergic system, but not between peripheral noradrenergic denervation and circulating noradrenergic levels.</div></div>","PeriodicalId":33691,"journal":{"name":"Clinical Parkinsonism Related Disorders","volume":"12 ","pages":"Article 100346"},"PeriodicalIF":1.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143943409","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Integrating tele-palliative care for atypical Parkinsonian disorders: Lessons learned from a pilot program","authors":"Mitra Afshari ,&nbsp;Kyurim Kang ,&nbsp;Ankur A. Butala ,&nbsp;Jana Guenther ,&nbsp;Rab Razzak ,&nbsp;Maya Katz ,&nbsp;Nicholas B. Galifianakis ,&nbsp;Alexander Pantelyat","doi":"10.1016/j.prdoa.2025.100352","DOIUrl":"10.1016/j.prdoa.2025.100352","url":null,"abstract":"<div><h3>Introduction</h3><div>As evidence supporting palliative care (PC) via tele-medicine for neurologic patients increases, it is important to determine the best integration methods across various healthcare settings and patient populations to optimize outcomes. Given the rising demand for PC in chronic neurodegenerative diseases like Atypical Parkinsonian Disorders (APDs), it is imperative to explore different models of PC delivery for feasibility and effectiveness.</div></div><div><h3>Methods</h3><div>Participants with APDs and their care partners at the University of California, San Francisco (UCSF) and Johns Hopkins University (JHU) received 2 virtual telemedicine PC sessions (at baseline and 6 months). Adherence and feasibility-related outcomes were assessed using a satisfaction survey developed by the investigators, using a five-point Likert scale, administered at baseline and 6 months. Additionally, participants’ quality of life (QoL), mood, functional abilities, and care partner burden were assessed at baseline and 6-month follow-up virtual visits.</div></div><div><h3>Results</h3><div>There was a 100 % attendance rate among participants and their care partners at both sites. Satisfaction levels regarding visit convenience were &gt; 78 % for both visits at UCSF and reached 100 % at JHU. No significant differences were observed between baseline and 6-month assessments at both sites in QoL, mood, or caregiver burden. However, there was a significant decrease in functional abilities during the second visit (6 months) at JHU.</div></div><div><h3>Conclusion</h3><div>These results support the integration and expansion of telemedicine PC services to address the evolving needs of individuals with APDs and their care partners, offering a viable solution to enhance access to PC in diverse healthcare settings.</div></div>","PeriodicalId":33691,"journal":{"name":"Clinical Parkinsonism Related Disorders","volume":"12 ","pages":"Article 100352"},"PeriodicalIF":1.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144147261","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Speech subtypes are associated with worsened tremor and axial symptoms in Parkinson’s disease patients","authors":"Vanessa Brzoskowski dos Santos ,&nbsp;Rafaela Ravazio ,&nbsp;Daniel Teixeira-dos-Santos ,&nbsp;Artur Francisco Schumacher Schuh ,&nbsp;Christian Mattjie ,&nbsp;Joana M. Pasquali ,&nbsp;Mauricia Denise de Borba ,&nbsp;Rodrigo C Barros ,&nbsp;Maira Rozenfeld Olchik","doi":"10.1016/j.prdoa.2025.100373","DOIUrl":"10.1016/j.prdoa.2025.100373","url":null,"abstract":"<div><h3>Background</h3><div>Parkinson’s disease (PD) is a heterogeneous disorder, suggesting the presence of distinct subtypes. Speech data, though easy to collect, remains underutilized in subtyping PD.</div></div><div><h3>Methods</h3><div>Cross-sectional study with PD patients recruited from the Movement Disorders Outpatient Clinic of the Neurology Service at the University Hospital in Porto Alegre, Brazil. We included participants diagnosed with idiopathic PD and excluded participants with other disorders that could affect speech. Clinical and sociodemographic data were collected alongside MDS-UPDRS Parts II and III motor assessments. Tremor and gait-posture scores were derived from specific MDS-UPDRS items, with additional data on Deep Brain Stimulation (DBS) status and Levodopa Equivalent Daily Dose (LEDD). The tasks diadochokinesis (DDK) and monologue were recorded and acoustically analyzed using software. We compared our identified clusters using clinical data through an analysis of covariance adjusted for age, sex, and disease duration.</div></div><div><h3>Results</h3><div>Ninety individuals with PD were included, with 61.2 (± 9.4) years old, 13.6 (± 6.6) disease duration, and 47.6 (± 10) age at onset. We identified three speech groups with strong separation between them, comprising 49 (mild), 13 (moderate), and 29 (severe) patients. Tremor and postural-gait stability scores differed significantly across the three clusters, with cluster 3 exhibiting higher tremor (13.42 ± 10.66 vs. 7.09 ± 6.62, p = 0.020) and greater postural-gait instability (10.25 ± 6.69 vs. 5.46 ± 4.91, p = 0.009) than cluster 1. These differences weren’t explainable by distinct age, sex, or disease duration.</div></div><div><h3>Conclusion</h3><div>Our speech-based clustering algorithm effectively differentiated Parkinson’s disease subtypes in this sample, identifying distinct groups based on tremor and axial symptoms.</div></div>","PeriodicalId":33691,"journal":{"name":"Clinical Parkinsonism Related Disorders","volume":"13 ","pages":"Article 100373"},"PeriodicalIF":1.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144721806","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Validation of the English version of the Parkinson Anxiety Scale in two Canadian Parkinson’s disease samples","authors":"Joyce S.T. Lam ,&nbsp;Kira N. Tosefsky ,&nbsp;Xuyan Tang ,&nbsp;Dylan Meng ,&nbsp;Petra Uzelman ,&nbsp;Fabricio Pio ,&nbsp;Nicholas J. Ainsworth ,&nbsp;Fidel Vila-Rodriguez ,&nbsp;Andrew K. Howard ,&nbsp;Silke Appel-Cresswell","doi":"10.1016/j.prdoa.2025.100387","DOIUrl":"10.1016/j.prdoa.2025.100387","url":null,"abstract":"<div><h3>Introduction</h3><div>The 12-item Parkinson Anxiety Scale (PAS) assesses the severity of anxiety symptoms in people with Parkinson’s disease (PwP). However, psychometric evidence supporting the English self-rated PAS remains largely limited to validation studies by the developers. This study aimed to reinforce validation of this scale through a comprehensive psychometric evaluation in PwP in Canada.</div></div><div><h3>Methods</h3><div>Data were drawn from two Canadian samples of 130 and 53 PwP, respectively, at a tertiary center. Acceptability, reliability, validity, and factor structure were assessed. The Mini International Neuropsychiatric Interview was administered to confirm anxiety diagnoses. Optimal cut-off scores suggesting the presence of an anxiety disorder were determined using receiver operating characteristic (ROC) curve analysis.</div></div><div><h3>Results</h3><div>The PAS and its three subscales demonstrated good acceptability and internal consistency reliability (Cronbach’s α &gt; 0.70). Good convergent validity with the State-Trait Anxiety Inventory and divergent validity with scales assessing other non-motor symptoms were obtained. Confirmatory factor analysis supported the three-factor structure (comparative fit index = 0.987; Tucker-Lewis index = 0.983; root mean square error of approximation = 0.083; standardized root mean square residual = 0.087). Optimal cut-off scores were 12.5 for the total PAS (area under the ROC curve = 0.81, sensitivity = 0.89, specificity = 0.58), 8.5 for the persistent anxiety subscale, and 2.5 for the episodic anxiety and avoidance behavior subscales. Approximately 22 % of participants in the larger sample had a diagnosed anxiety disorder.</div></div><div><h3>Conclusion</h3><div>The English self-rated PAS is a valid and reliable instrument for screening and assessing severity and dimensions of anxiety in PwP.</div></div>","PeriodicalId":33691,"journal":{"name":"Clinical Parkinsonism Related Disorders","volume":"13 ","pages":"Article 100387"},"PeriodicalIF":1.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144853030","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cognition is associated with daily-life mobility in people with Parkinson’s disease","authors":"Pablo I. Burgos ,&nbsp;Carla Silva-Batista ,&nbsp;Anjanibhargavi Ragothaman ,&nbsp;Vrutangkumar V. Shah ,&nbsp;Patricia Carlson-Kuhta ,&nbsp;Fay B. Horak ,&nbsp;Martina Mancini","doi":"10.1016/j.prdoa.2025.100393","DOIUrl":"10.1016/j.prdoa.2025.100393","url":null,"abstract":"<div><h3>Introduction</h3><div>Cognitive impairment is common in people with Parkinson’s disease (PD). Mobility is also impaired in people with PD and functional mobility often requires cognitive dual-tasking to navigate complex environments in daily life. We hypothesized that visuospatial and executive cognitive dysfunction in people with PD will be associated with digital measures of mobility in daily life. Since freezing of gait (FoG) is associated with both cognitive dysfunction and mobility impairments, we also examined the influence of FoG on the cognition-mobility relationship. Here, we investigated, for the first time, the association between cognition and daily-life mobility in PD and the influence of FoG status.</div></div><div><h3>Methods</h3><div>60 individuals with mild-to-moderate PD (17 with FoG and 43 without FoG) wore 3 inertial sensors (lumbar and feet) for a week of passive monitoring of mobility. Digital visuospatial (Line Orientation task) and executive tasks (Set-Shifting and Flanker task) were assessed in the ON medication state.</div></div><div><h3>Results</h3><div>Visuospatial function was significantly associated with gait speed (r = -0.46, p = 0.008) and stride length (r = -0.40, p = 0.022). Set Shifting was significantly associated with stance time (r = -0.35, p = 0.046), double support time (r = -0.35, p = 0.046), and the variability of step duration during turning (r = 0.44, p = 0.016). The Flanker test was not associated with any gait variables. FoG status was less important than disease duration or age in the cognitive-mobility associations.</div></div><div><h3>Conclusions</h3><div>Specific types of cognition were related to specific gait variables in daily life. People with PD with worse visuospatial functions had worse gait pace. In contrast, participants with worse executive function (set-switching) had worse dynamic postural control during gait. FoG status showed minimal influence on these associations.</div></div>","PeriodicalId":33691,"journal":{"name":"Clinical Parkinsonism Related Disorders","volume":"13 ","pages":"Article 100393"},"PeriodicalIF":1.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145044589","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advance care planning in Hispanic populations with Parkinson’s Disease: Investigating disparities in end-of life care","authors":"Taylor Peabody ,&nbsp;Monica Abou-Ezzi ,&nbsp;Lucila Hernandez ,&nbsp;Henry Moore ,&nbsp;Silvia Vargas-Parra ,&nbsp;Alberto Cruz ,&nbsp;Danielle S. Shpiner","doi":"10.1016/j.prdoa.2025.100388","DOIUrl":"10.1016/j.prdoa.2025.100388","url":null,"abstract":"<div><h3>Introduction</h3><div>Advance care planning (ACP) is a tool for optimizing end-of-life care and is an important aspect of healthcare for people with Parkinson’s disease (PD). However, there may be disparities in access to ACP based on race and/or ethnicity.</div></div><div><h3>Methods</h3><div>We conducted a cross-sectional survey of people with PD and care partners from a diverse academic Movement Disorders clinic regarding familiarity with ACP and sociodemographic factors. We compared prior experiences with ACP, with a primary outcome examining prior completion of healthcare power of attorney (HPOA) and advance directives (AD) among Hispanics and non-Hispanics in the cohort. Univariate analysis was utilized to compare cohort demographics. A multinomial logistic regression was performed to control for possible confounders.</div></div><div><h3>Results</h3><div>250 participants completed the survey, including 116 (46.4 %) who self-identified as Hispanic and 127 (50.8 %) non-Hispanic. Only 20 % of Hispanic participants had previously completed HPOA documentation versus 66.9 % non-Hispanics (p &lt; 0.001). The rates of completion for AD were 6.1 % and 31.7 %, respectively (p &lt; 0.001). Hispanic respondents were less likely to have heard about these documents and more likely to wait until later in the disease course to discuss ACP, despite a majority viewing these discussions as important. These trends remained when controlling for several demographic variables; however, age and preferred language of survey emerged as potential confounders for some answer choices.</div></div><div><h3>Conclusions</h3><div>Hispanic people with PD may be less likely to utilize ACP than their non-Hispanic counterparts. Awareness of these resources or cultural factors may play a role and should be explored further in future studies.</div></div>","PeriodicalId":33691,"journal":{"name":"Clinical Parkinsonism Related Disorders","volume":"13 ","pages":"Article 100388"},"PeriodicalIF":1.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144828273","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A single Center study of the Symbol Digit Modalities test as a screening tool for cognitive impairment in Parkinson’s disease","authors":"Daniyell Thomason ,&nbsp;Morganne Manuel ,&nbsp;Shannin Moody ,&nbsp;Jesus Lovera ,&nbsp;Brain Copeland ,&nbsp;Deidre Devier","doi":"10.1016/j.prdoa.2025.100395","DOIUrl":"10.1016/j.prdoa.2025.100395","url":null,"abstract":"<div><h3>Background</h3><div>Parkinson’s Disease (PD) can include physical signs and possibly cognitive impairment, resulting from the convergence of pathological<!--> <!-->processes involving dopaminergic dysfunction, accumulation of<!--> <!-->alpha-synuclein, cholinergic deficits, and disruption of other<!--> <!-->neurotransmitter systems. We used screening tests to evaluate the<!--> <!-->characteristics of cognitive performance in patients with PD and to assess their validity compared to<!--> <!-->the Montreal Cognitive Assessment (MoCA).</div></div><div><h3>Methods</h3><div>This is a natural history study of participants with PD and controls screened for possible cognitive impairment using the MoCA, Symbol Digit Modalities Test (SDMT), and King-Devick (KD). The groups were compared on performance and then factors associated with cognitive performance (age, diagnosis, and level of education) were analyzed to determine which best predicted test scores.</div></div><div><h3>Results</h3><div>SDMT scores were lower in the PD group (Mean = 36.7 ± 12.4) compared to controls (Mean = 47.2 ± 11.0, p &lt; 0.001), but the MoCA (PD = 23.8 ± 3.5; Control = 25.5 ± 3.6, p = 0.02) and KD (PD = 70.1 ± 23.4 s; Control = 61.6 ± 17.5, p = 0.048) did not differentiate between groups after controlling for multiple comparisons. Age and diagnosis predicted SDMT raw scores and, as expected, only diagnosis remained significant after calculating T-scores based on published test norms. Age, education, and diagnosis predicted MoCA scores.</div></div><div><h3>Conclusions</h3><div>The SDMT emerged as a promising screening tool to detect cognitive impairment in PD. The test’s age and education corrected norms controlled for those variables and left diagnosis as the only predictor of performance. The MoCA scores were predicted by age, education, and diagnosis suggesting the education correction of the MoCA did not fully account for the influence of demographic variables.</div></div>","PeriodicalId":33691,"journal":{"name":"Clinical Parkinsonism Related Disorders","volume":"13 ","pages":"Article 100395"},"PeriodicalIF":1.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145104200","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Leukoaraiosis does not impact motor outcomes in Parkinson’s patients post deep brain stimulation","authors":"Heather Martin ,&nbsp;Rushna Ali ,&nbsp;Ashok Sriram ,&nbsp;Robert Coleman ,&nbsp;Emily Ruether ,&nbsp;Hayden Boyce ,&nbsp;Morgan L. Maley ,&nbsp;Muhib Khan","doi":"10.1016/j.prdoa.2025.100348","DOIUrl":"10.1016/j.prdoa.2025.100348","url":null,"abstract":"<div><h3>Objectives</h3><div>We sought to assess the impact of leukoaraiosis (LA) on motor outcomes in Parkinson disease (PD) patients undergoing DBS. We hypothesized that LA is associated with less improvement in motor function in PD patients post-DBS.</div></div><div><h3>Methods</h3><div>We reviewed data of adult patients with PD treated with DBS in a single center between 2012 and 2021. Demographics, risk factors, medications, Hoehn and Yahr scale and Unified Parkinson’s Disease Rating Scale (UPDRS) Motor Score before and after DBS and severity of LA were collected. Simple linear regression (SLR) was used to determine variables of interest to include in the multiple linear regression (MLR). MLR was used to determine independent predictors of motor outcomes (UPDRS) post-DBS including LA as a continuous and dichotomized variable of interest.</div></div><div><h3>Results</h3><div>A total of 90 patients were included in the analysis. Mean age was 65.7 years (±9.7), primarily male (69 %) with a high incidence of young onset PD (29 %), treated with carbidopa/levodopa combination (98 %) and with moderate severity of disease (Hoehn and Yahr Stage 2.0 [2.0, 2.5]). Moderate to severe leukoaraiosis was noted in 26 (32.5 %) patients. SLR revealed age, diabetes and disease severity as predictors of post-DBS motor UPDRS. In adjusted analysis, LA was not an independent predictor of motor outcomes post-DBS either as continuous (β = 0.20, p = 0.77) or dichotomized (β = −0.64; p = 0.77) variable.</div></div><div><h3>Conclusion</h3><div>In conclusion, our data suggests that motor outcomes in Parkinson’s disease patients undergoing deep brain stimulation (DBS) are not impacted by pre-existing leukoaraiosis. Further studies are needed to validate our findings.</div></div>","PeriodicalId":33691,"journal":{"name":"Clinical Parkinsonism Related Disorders","volume":"12 ","pages":"Article 100348"},"PeriodicalIF":1.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143948216","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessment of social isolation and changes in Parkinson’s disease symptoms during the COVID-19 pandemic: A longitudinal study","authors":"Anish Mehta ,&nbsp;Samuel Y.E. Ng ,&nbsp;Shermyn X.M. Neo ,&nbsp;Nicole S.Y. Chia ,&nbsp;Ehsan S. Saffari ,&nbsp;Thyagarajan Shivashanmugam ,&nbsp;Xinyi Choi ,&nbsp;Dede L. Heng ,&nbsp;Z.Y. Xu ,&nbsp;K.Y. Tay ,&nbsp;W.L. Au ,&nbsp;E.K. Tan ,&nbsp;Louis C.S. Tan","doi":"10.1016/j.prdoa.2024.100293","DOIUrl":"10.1016/j.prdoa.2024.100293","url":null,"abstract":"<div><h3>Background</h3><div>COVID-19-related social restrictions provided an opportunity to evaluate the impact of social isolation on Parkinson’s disease.</div></div><div><h3>Objective</h3><div>This study aimed to explore changes in social isolation and their associations with PD symptoms using the Lubben Social Network Scale-Revised (LSNS-R).</div></div><div><h3>Methods</h3><div>Data from 80 participants of the Early Parkinson’s Disease Longitudinal Singapore cohort were collected from April 2019 to April 2023, covering the periods before and after the imposition of COVID-19 restrictions. Individuals with LSNS-R scores ≤ 24 were considered socially isolated. Data were stratified into strata 1 (improved LSNS-R scores) and strata 2 (worsened/unchanged scores). Linear regression was used to identify predictors of LSNS-R change, and MANCOVA was used to examine associations between LSNS-R change and motor/ non-motor symptoms.</div></div><div><h3>Results</h3><div>Mean LSNS-R scores decreased (p = 0.014), and proportions of social isolation increased (p &lt; 0. 001) during COVID-19 restrictions. However, 35 % showed improved LSNS-R scores, while 65 % had worsened/unchanged scores. The regression model was significant in strata 1 (R2 = 0.806, p = 0.001), with age, marital status, and social isolation status being significantly associated with change in LSNS-R scores. LSNS-R. Results of MANCOVA indicated that LSNS-R improvements in LSNS-R were significantly associated with outcomes (Roy’s Largest Root statistic = 126.638, p &lt; 0.001), particularly for changes in PDQ8, HADS-Anxiety, and HADS-Depression scores. The regression model was not significant in strata 2 (R2 = 0. 279, p = 0.206), wherein motor and non-motor symptoms worsened.</div></div><div><h3>Conclusion</h3><div>While worsening LSNS-R scores were associated with poorer outcomes, improvements in social networks were associated with improved non-motor symptoms and quality of life. These findings underscore the complexity of social isolation in PD and the need for targeted interventions.</div></div>","PeriodicalId":33691,"journal":{"name":"Clinical Parkinsonism Related Disorders","volume":"12 ","pages":"Article 100293"},"PeriodicalIF":1.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11696853/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142932879","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identification of inverted U-shaped curve association between serum potassium and prodromal Parkinson’s disease","authors":"Wen Zhou,&nbsp;Qingqing Xia,&nbsp;Duan Liu,&nbsp;Jun-ying Li,&nbsp;Liang Gong","doi":"10.1016/j.prdoa.2025.100323","DOIUrl":"10.1016/j.prdoa.2025.100323","url":null,"abstract":"<div><h3>Background</h3><div>The association between serum potassium and prodromal Parkinson’s disease (PPD) remains unclear currently.</div></div><div><h3>Objective</h3><div>The ultimate goal is to gain a deeper understanding of the implications of this association between serum potassium and PPD.</div></div><div><h3>Methods</h3><div>We conducted a retrospective cross-sectional study involving 1035 participants in PPMI cohort. Age, sex, education years, race, body mass index (BMI), calcium, alanine aminotransferase, aspartate aminotransferase, lymphocytes, neutrophils, serum uric acid, serum sodium, serum potassium, creatinine, serum glucose were obtained from all participants. Logistic regression, and smooth curve fitting were utilized to substantiate the research objectives.</div></div><div><h3>Results</h3><div>The overall PPD was 83.4 % (863/1035). Multivariate odds ratio regression adjusted for risk factors demonstrates a 1-unit increment in the serum potassium raises the risk of PPD by 1.82 times, respectively. Smooth splines analysis suggested an inverted U-shaped association between serum potassium and PPD (P nonlinearity &lt; 0.05), with the zenith of risk at 4.479 mmol/L. Further subgroup analysis and sensitivity analyses supported the primary findings and indicated the conclusions are robust.</div></div><div><h3>Conclusions</h3><div>This study highlights the association between serum potassium levels and the risk of incident PPD, independent of confounders. The association between serum potassium and PPD is inverted U-shaped, the threshold value is 4.479 mmol/l.</div></div>","PeriodicalId":33691,"journal":{"name":"Clinical Parkinsonism Related Disorders","volume":"12 ","pages":"Article 100323"},"PeriodicalIF":1.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143821263","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}